A randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain

Pain Medicine (United States)

Volumn 15, Issue 11, 2014, Pages 1825-1834

  Cryer, Byron ^a,b   Katz, Seymour ^c   Vallejo, Ricardo ^d   Popescu, Anca ^e,h   Ueno, Ryuji ^f,g  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^c Long Island Clinical Research Associates   (United States)

^d MILLENNIUM PAIN CENTER   (United States)

^e THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^f Sucampo Pharma Americas   (United States)

^g Sucampo AG   (Switzerland)

^h Department of Anesthesiology   (United States)

Author keywords

Bowel Movement; ClC 2; Opioid; Opioid Induced Constipation; Placebo Controlled Trial; Prostone

Indexed keywords

HYDROCODONE; LUBIPROSTONE; MORPHINE; OPIATE; OXYCODONE; PLACEBO; CHLORIDE CHANNEL STIMULATING AGENT; NARCOTIC ANALGESIC AGENT; PROSTAGLANDIN E1;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ADULT; ALASKA NATIVE; AMERICAN INDIAN; ARTICLE; ASIAN; BLACK PERSON; BLOATING; CAUCASIAN; CHRONIC NONCANCER PAIN; CHRONIC PAIN; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HARD FECES; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; OPIOID INDUCED CONSTIPATION; PAIN SEVERITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TREATMENT DURATION; VOMITING; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL;

ALPROSTADIL; ANALGESICS, OPIOID; CHLORIDE CHANNEL AGONISTS; CHRONIC PAIN; CONSTIPATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LUBIPROSTONE; MALE; MIDDLE AGED;

EID: 84911991195     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/pme.12437     Document Type: Article

References (26)

1. Johannes CB, Le TK, Zhou X, Johnston JA, Dworkin RH. The prevalence of chronic pain in United States adults: Results of an internet-based survey. J Pain 2010;11:1230-1239.
2. Loyland B, Miaskowski C, Wahl AK, Rustoen T. Prevalence and characteristics of chronic pain among long-term social assistance recipients compared to the general population in Norway. Clin J Pain 2010;26:624-630.
3. Ohayon MM, Stingl JC. Prevalence and comorbidity of chronic pain in the German general population. J Psychiatr Res 2012;46:444-450.
4. IOM (Institute of Medicine). Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington, DC: The National Academies Press; 2011.
5. Fine PG, Mahajan G, McPherson ML. Long-acting opioids and short-acting opioids: Appropriate use in chronic pain management. Pain Med 2009;10:S79-88.
6. Kurz A, Sessler DI. Opioid-induced bowel dysfunction: Pathophysiology and potential new therapies. Drugs 2003;63:649-671.
7. Holzer P. Opioid receptors in the gastrointestinal tract. Regul Pept 2009;155:11-17.
8. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: Systematic review of efficacy and safety. Pain 2004;112:372-380.
9. Bell TJ, Panchal SJ, Miaskowski C, etal. The prevalence, severity, and impact of opioid-induced bowel dysfunction: Results of a US and European Patient Survey (PROBE 1). Pain Med 2009;10:35-42.
10. ® (lubiprostone). Full Prescribing Information, Sucampo Pharma Americas, LLC, Bethesda, MD, and Takeda Pharmaceuticals America, Inc., Deerfield, IL, USA, 2013.
11. Lacy BE, Levy LC. Lubiprostone: A chloride channel activator. J Clin Gastroenterol 2007;41:345-351.
12. Fei G, Raehal K, Liu S, etal. Lubiprostone reverses the inhibitory action of morphine on intestinal secretion in guinea pig and mouse. J Pharmacol Exp Ther 2010;334:333-340.
13. Ueno R, Hiroyoshi O, Engelke K. Lubiprostone effects on morphine-induced constipation and analgesia. Gastroenterology 2006;130:A373.
14. Johanson JF, Morton D, Geenen J, Ueno R. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol 2008;103:170-177.
15. Barish CF, Drossman D, Johanson JF, Ueno R. Efficacy and safety of lubiprostone in patients with chronic constipation. Dig Dis Sci 2010;55:1090-1097.
16. Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: A double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther 2007;25:1351-1361.
17. Quigley C. The role of opioids in cancer pain. BMJ 2005;331:825-829.
18. Camilleri M. Opioid-induced constipation: Challenges and therapeutic opportunities. Am J Gastroenterol 2011;106:835-842, quiz 43.
19. ® (methylnaltrexone bromide). Full Prescribing Information, Wyeth Pharmaceuticals, Inc., Philadelphia, PA, USA, 2010.
20. Lowenstein O, Leyendecker P, Lux EA, etal. Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: Results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials. BMC Clin Pharmacol 2010;10:12.
21. Paulson DM, Kennedy DT, Donovick RA, etal. Alvimopan: An oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction-A 21-day treatment-randomized clinical trial. J Pain 2005;6:184-192.
22. Webster L, Jansen JP, Peppin J, etal. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: Results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain 2008;137:428-440.
23. Jansen JP, Lorch D, Langan J, etal. A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. J Pain 2011;12:185-193.
24. Irving G, Penzes J, Ramjattan B, etal. A randomized, placebo-controlled phase 3 trial (Study SB-767905/013) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. J Pain 2011;12:175-184.
25. ® (alvimopan). Full Prescribing Information, Cubist Pharmaceuticals, Inc, Lexington, MA, USA, 2013.
26. Joswick T, Spierings ELH, Lindner E, Woldegeorgis F, Ueno R. Analgesia during long-term lubiprostone therapy in patients with opioid-induced constipation and chronic, non-cancer pain: Results from a phase 3, open-label clinical trial. J Pain 2013;14(suppl):s79. American Pain Society 32nd Annual Meeting; May 8-11, 2013; New Orleans, LA.